Treadmill test shows who Ampligen may help

Drug company research team identifies which CFS patients may respond best to Ampligen
Hemispherx Biopharma has identified new criteria to see which CFS patients may get significant clinical benefit from Ampligen (rintatolimod). Patients who are able to complete more than 9 minutes of exercise (modified Bruce protocol exercise tolerance test) are likely to benefit from Ampligen.
Data from a previous Phase III clinical trial of Ampligen were analysed to determine whether baseline exercise tolerance could be used to predict responses to Ampligen  vs. placebo in CFS patients. A modified treadmill test was used because of the severe physical exercise intolerance of CFS patients. The paper uses both 1988 Holmes criteria and 1994 Fukuda criteria to define CFS patients.
For patients with baseline exercise tolerance of more than 9 minutes, 33% of patients on Ampligen improved exercise tolerance duration by 25% or more (vs. 12% of patients on placebo), while 23% of Ampligen-treated patients improved by 50% or more (compared to 4.5% placebo patients).
There was also a group of patients identified who, although termed ‘non responders’, had their deterioration slowed by taking Ampligen.
What prompted this research?
This study was prompted by the Phase III clinical trial, where patients were given Ampligen twice weekly for 40 weeks compared to placebo. Some patients dramatically responded while others did not. Their hypothesis was that baseline exercise tolerance could be used to predict responses to rintatolimod. This report identifies three classes of patients. The first is defined by marked improvement in exercise tolerance and quality of life. The second class was not significantly responsive. The third class, although deteriorating on rintatolimod, do so at a reduced rate compared to controls.
Full paper: Published in the Journal of Drug Research and Development, the paper is Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): Characteristics of Responders to Rintatolimod.
 

Facebook
Twitter
WhatsApp
Email

Latest News

SOS: Save our Science

People disabled by ME and Long Covid across the UK send out an SOS.  It’s time to send out our SOS signal, if we want to have funded research. May 12th, is Myalgic Encephalomyelitis Awareness Day. On this day, the #MillionsMissing of people with myalgic encephalomyelitis (ME) gather to demand an increase in research and

Read More »
a blue square image that features waves as the background. The 2025 #MillionsMissing logo at the top. followed by the words, Why We're sending out an SOS. A life preserver is in the bottom right corner and the meaction logo is in the bottom left corner.

Why We’re Sending out an SOS this #MillionsMissing

On May 12th, #MEAction and the #MillionsMissing are sending out an SOS to Congress to Save our Support Systems. Save our Science. Save Our Society.  HERE’S WHY: Healthcare, research funding and accessibility were already incredibly fragile for people with myalgic encephalomyelitis (ME), Long Covid and the disability communities. Now, we are seeing constant threats to

Read More »

Writers Guild Initiative Writing Workshops: Apply Today

#MEAction is excited to announce we are partnering with the Writers Guild Initiative (WGI) again to offer creative writing workshops for people with ME and Long COVID**. WGI has graciously donated their time to offer these writer workshops through personal mentorship with the writers of the #MEAction community! The workshops consist of three sessions during

Read More »
Scroll to Top